Modality
Radioligand
MOA
WRNi
Target
PD-L1
Pathway
Proteasome
Celiac
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
→ Sep 2030
Phase 2Current
NCT04518331
1,264 pts·Celiac
2021-07→2027-08·Terminated
NCT04664615
773 pts·Celiac
2020-09→2030-09·Recruiting
2,037 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-08-171.4y awayPh3 Readout· Celiac
2030-09-254.5y awayPh3 Readout· Celiac
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Termina…
Catalysts
Ph3 Readout
2027-08-17 · 1.4y away
Celiac
Ph3 Readout
2030-09-25 · 4.5y away
Celiac
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04518331 | Phase 2/3 | Celiac | Terminated | 1264 | UPCR |
| NCT04664615 | Phase 2/3 | Celiac | Recruiting | 773 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |